Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label dose escalation study of AAV2/2-hRPE65p-hRPE65 gene therapy in severe early-onset retinal degeneration
2006-001571-37Phase 2Completed
- Sponsor
- University College London
- Start
- Nov 2008
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AAV2/2-hRPE65p-hRPE65 in Fundus dystrophy and Retinal atrophy, sponsored by University College London. Primary endpoint: Visual function improvement beyond test-retest variation. Started Nov 2008; status: completed.
02
Drugs
AAV2/2-hRPE65p-hRPE65
03
Conditions
Fundus dystrophyRetinal atrophy
Beyond the preview
Go deeper on 2006-001571-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001571-37.